ASCO GU 2018 Prostate Cancer - Results from #60

Viewing 61-80 of 88 articles

ASCO GU 2018: Impact of 2012 USPSTF Prostate Cancer Screening Recommendations on Prostate Cancer Detection and Presentation at Kaiser Permanente Northern California (KPNC)

ASCO GU 2018: Prospective Analysis of 4,474 Prostate Biopsies to Evaluate Potential Treatment Management Impact of Combined Clinical-genomic Risk Classification

ASCO GU 2018: Life After Prostate Cancer Diagnosis: One Step Beyond

ASCO GU 2018: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer.

ASCO GU 2018: Review of First Presentation: SPARTAN and PROSPER

ASCO GU 2018: First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer

ASCO GU 2018: First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

ASCO GU 2018: Transcriptomic Heterogeneity of Androgen Receptor Activity in Primary Prostate Cancer: Identification and Characterization of a Low AR-active Subclass

ASCO GU 2018: Medical Resource Utilization of Abiraterone Acetate Plus Prednisone added to ADT in Metastatic Castration-naive Prostate Cancer: Results from LATITUDE

ASCO GU 2018: Management of Oligometastatic Prostate Cancer From Imaging to Therapy

ASCO GU 2018: Impact of Decipher test on adjuvant and salvage treatments received following radical prostatectomy

ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-sensitive Prostate Cancer

ASCO GU 2018: Shared decision making for prostate cancer screening: Reality or farce?

ASCO GU 2018: The FALCON Trial: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer

ASCO GU 2018: Emerging Immunotherapy Strategies for Castrate Resistant Prostate Cancer

ASCO GU 2018: Improving risk-stratification of localized prostate cancer in a prospective active surveillance cohort

ASCO GU 2018: Enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic CRPC patients metastatic to bone (PEACE III)

ASCO GU 2018: Molecular Therapies in Bone Metastases

ASCO GU 2018: Genomic and Phenotypic Evidence for Prostate Cancer Osteomimicry in Circulating Tumor Cells from Men with Metastatic Castration Resistant Prostate Cancer Treated with Radium-223

ASCO GU 2018: Multivitamin Use and Risk of Prostate Cancer Recurrence: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)

1
2
3
4
5